Abciximab contraindications: Difference between revisions

Jump to navigation Jump to search
Gerald Chi (talk | contribs)
mNo edit summary
 
Gerald Chi (talk | contribs)
mNo edit summary
Line 6: Line 6:


Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:
Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:
* Active internal bleeding
* Active internal bleeding
* Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.
* Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.
* History of cerebrovascular accident ([[CVA]]) within two years, or [[CVA]] with a significant residual neurological deficit
* History of [[CVA|cerebrovascular accident (CVA)]] within two years, or [[CVA]] with a significant residual neurological deficit
* Bleeding diathesis
* Bleeding diathesis
* Administration of oral [[anticoagulant]]s within seven days unless [[prothrombin time]] is <1.2 times control
* Administration of oral [[anticoagulant]]s within seven days unless [[prothrombin time]] is <1.2 times control

Revision as of 20:00, 29 January 2014

Template:Abciximab Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2], Pratik Bahekar, MBBS [3]

Contraindications

Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:

References

  1. "REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY]".

Adapted from the FDA Package Insert.